Objectives. We estimated anogenital wart prevalence from 2003 to 2010 by gender and age
group in a large US cohort with private insurance to detect potential decreases among …

Objectives: The cost-effectiveness of adding a human papillomavirus (HPV) vaccination
program in 12-year-old females to the recommended cervical cancer screening in Belgium …

Objectives Since the introduction of Australia's human papillomavirus vaccination program,
the management rate of genital warts in sexual health clinics and private hospitals has …

The treatment of genital warts remains frustrating since it is often painful, expensive, and
unsuccessful. Moreover, little is known about the infectivity and natural history of exophytic …

Human papillomavirus (HPV) infection, usually a sexually transmitted disease, is a risk factor
for cervical cancer. Given the substantial disease and death associated with HPV and …

Abstract Background In Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is
offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine …

Abstract Background and Objectives Giving the human papillomavirus (HPV) vaccination to
females has been shown to be cost-effective in most countries. The epidemiological …

Background. Diagnoses of genital warts (GW) in genitourinary medicine (GUM) clinics have
been increasing in England for many years. In 2008, an HPV immunization program began …

ABSTRACT Introduction: Since 2007, the German Standing Vaccination Committee
recommends HPV vaccination for girls aged 12–17 with a 2-(Cervarix®) or 4-valent …

Background Increasing evidence suggests that 1-dose human papillomavirus (HPV)
vaccination may protect significantly against HPV-related disease. We provide nationwide …